The clinical efficacy and cardiotoxicity of fixed-dose monthly trastuzumab in HER2-positive breast cancer: A single institutional analysis

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Wu, Yi Ying ^a,b   Huang, Tzu Chuan ^a   Tsai, Tsung Neng ^a,b   Chen, Jia Hong ^a,c   Dai, Ming Shen ^a   Chang, Ping Ying ^a   Ho, Ching Liang ^a   Ye, Ren Hua ^a   Chung, Tsai Rong ^d   Chen, Yeu Chin ^a   Chao, Tsu Yi ^b,c,e  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d National Institute of Cancer Research   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER STAGING; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; BREAST NEOPLASMS; CARDIOTOXICITY; CARDIOVASCULAR DISEASES; DISEASE COURSE; FEMALE; FOLLOW UP; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOTOXICITY; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84961131596     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151112     Document Type: Article

References (29)

1. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature reviews Cancer. 2004; 4(5):361-70. Epub 2004/05/04. doi: 10.1038/nrc1360 PMID: 15122207.
2. Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(28):4423-30. Epub 2007/10/02. doi: 10.1200/JCO.2007.11.0973 PMID: 17906205.
3. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002; 20 (3):719-26. Epub 2002/02/01. PMID: 11821453.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine. 2001; 344(11):783-92. Epub 2001/03/15. doi: 10.1056/ NEJM200103153441101 PMID: 11248153.
5. Puputti M, Sihto H, Isola J, Butzow R, Joensuu H, Nupponen NN. Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. Cancer genetics and cytogenetics. 2006; 167(1):32-8. Epub 2006/05/10. doi: 10.1016/j.cancergencyto.2004.09.023 PMID: 16682283.
6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr., Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England journal of medicine. 2005; 353(16):1673-84. Epub 2005/10/21. doi: 10.1056/NEJMoa052122 PMID: 16236738.
7. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(8):1231-8. Epub 2008/02/06. doi: 10.1200/JCO.2007.13.5467 PMID: 18250349; PubMed Central PMCID: PMC4048960.
8. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumabassociated cardiac adverse effects in the herceptin adjuvant trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(25):3859-65. Epub 2007/07/25. doi: 10.1200/JCO.2006.09.1611 PMID: 17646669.
9. Belkacemi Y, Gligorov J, Ozsahin M, Marsiglia H, De Lafontan B, Laharie-Mineur H, et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2008; 19(6):1110-6. doi: 10.1093/annonc/mdn029 PMID: 18344537.
10. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumabrelated cardiotoxicity: new insights based on clinical course and response to medical treatment. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(31):7820-6. Epub 2005/11/01. doi: 10.1200/JCO.2005.13.300 PMID: 16258084.
11. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007; 369(9555):29-36. Epub 2007/01/09. doi: 10.1016/S0140-6736(07)60028-2 PMID: 17208639.
12. Pearson SA, Ringland CL, Ward RL. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia - monitoring the effect of an expensive medicine access program. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(24):3688-93. Epub 2007/ 08/21. doi: 10.1200/JCO.2007.11.2516 PMID: 17704417.
13. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17 (9):2639-48. PMID: 10561337.
14. Joensuu H, Kellokumpu-Lehtinen P, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. New Engl J Med. 2006; 354(8):809-20. doi: 10.1056/Nejmoa053028 PMID: WOS:000235456200005.
15. Slamon D, EiermannW, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. The New England journal of medicine. 2011; 365(14):1273-83. doi: 10.1056/NEJMoa0910383 PMID: 21991949; PubMed Central PMCID: PMC3268553.
16. Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, et al. Trastuzumab-containing regimens for metastatic breast cancer. The Cochrane database of systematic reviews. 2014; 6:CD006242. Epub 2014/06/13. doi: 10.1002/14651858.CD006242.pub2 PMID: 24919460.
17. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002; 105(13):1551-4. Epub 2002/04/03. PMID: 11927521.
18. Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. Journal of the National Cancer Institute. 2005; 97(6):419-24. Epub 2005/03/17. doi: 10.1093/jnci/dji067 PMID: 15770005; PubMed Central PMCID: PMC1853253.
19. Patt DA, Goodwin JS, Kuo YF, Freeman JL, Zhang DD, Buchholz TA, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(30):7475-82. Epub 2005/09/15. doi: 10.1200/JCO.2005.13.755 PMID: 16157933.
20. Onitilo AA, Engel JM, Stankowski RV. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Therapeutic advances in drug safety. 2014; 5(4):154-66. doi: 10.1177/2042098614529603 PMID: 25083270; PubMed Central PMCID: PMC4110857.
21. Russo G, Cioffi G, Gori S, Tuccia F, Boccardi L, Khoury G, et al. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. Journal of cardiovascular medicine. 2014; 15(2):141-6. doi: 10.2459/JCM.0b013e328365afb5 PMID: 24534802.
22. Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized doubleblind trial. JACC Heart failure. 2014; 2(6):641-9. doi: 10.1016/j.jchf.2014.06.008 PMID: 25282031.
23. Perez-Ellis C, Goncalves A, Jacquemier J, Marty M, Girre V, Roche H, et al. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer. American journal of clinical oncology. 2009; 32(5):492-8. Epub 2009/06/03. doi: 10.1097/COC.0b013e3181931277 PMID: 19487912.
24. Chan AL, Leung HW, Lu CL, Lin SJ. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review. The Annals of pharmacotherapy. 2009; 43(2):296-303. Epub 2009/02/06. doi: 10.1345/aph.1L504 PMID: 19193576.
25. Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. Health technology assessment. 2009; 13 Suppl 1:1-6. doi: 10.3310/hta13suppl1/01 PMID: 19567207.
26. Purmonen TT, Pankalainen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta oncologica. 2011; 50(3):344-52. Epub 2011/02/09. doi: 10.3109/0284186X.2011.553841 PMID: 21299447.
27. Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocrine-related cancer. 2002; 9(2):75-85. PMID: 12121832.
28. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(25):3910-6. doi: 10.1200/JCO. 2009.27.3615 PMID: 20679614.
29. Katsurada K, Ichida M, Sakuragi M, Takehara M, Hozumi Y, Kario K. High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy. Springer-Plus. 2014; 3:620. doi: 10.1186/2193-1801-3-620 PMID: 25392790; PubMed Central PMCID: PMC4216824.